Logo Image
|Slideshows|September 14, 2016

ADHD Research Update: September 2016

Three new studies in children with ADHD reveal an association with seizures, the benefits of after-school exercise, and brain changes linked to treatment.

References:

1. Bertelsen EN, Larsen JT, Petersen L, et al. Childhood epilepsy, febrile seizures, and subsequent risk of ADHD. Pediatrics. 2016;138:e20154654.
2. Bustamante EE, Davis CL, Frazier SL, et al. Randomized controlled trial of exercise for ADHD and disruptive behavior disorders. Med Sci Sports Exerc. 2016;48:1397-1407.
3. Schrantee A, Tamminga HGH, Bouziane C, et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder. JAMA Psychiatry. 2016;73:955-962.

Related Content

Latest CME

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care
Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

View more
Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia
Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

View more
Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia
Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

View more
Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder
Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

View more
(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia
Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

View more